Predicting and Preventing Adverse Maternal and Child Outcomes of Opioid Use Disorder in Pregnancy

Launched by ILANA HULL · Jul 3, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how to predict and prevent health problems for mothers and their babies when the mother has an opioid use disorder (OUD) during pregnancy. The researchers want to understand the effects of different treatments and how they can help improve outcomes for both the mother and child. They are looking for pregnant women who are currently receiving treatment for OUD, specifically those using medications like buprenorphine (BUP) or methadone (METH), and who plan to deliver at UPMC's Magee Womans Hospital.

To be eligible, women must be over 18 years old, have a single baby (not twins), and have tested positive for opioids in a urine test. The study will include around 100 participants over a year, with the possibility of some women dropping out. Participants can expect to be part of regular check-ups and will help researchers gather important health information. This study aims to improve care for pregnant women with OUD and ensure healthier outcomes for their babies.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Pregnant women with OUD and their infant
• • Currently on BUP/METH for OUD
• • Enrolled in prenatal opioid maintenance program
• • Age \>18 years
• • Singleton pregnancy
• • Planned delivery at UPMC's Magee Womans Hospital
• • Positive opioid urine screen results
• Exclusion Criteria:
• • Serious maternal medical illness as deemed by the PI that would make it challenging to comply with study procedures
• • HIV or AIDS
• • Known major fetal congenital abnormalities